These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1303696)

  • 1. Adjuvant properties of Propionibacterium avidum KP-40 in vaccination against endemic viral and bacterial infections. II. Swine immunized with inactivated Haemophilus pleuropneumoniae vaccine and experimentally infected with different virulent serotypes of H. pleuropneumoniae.
    Markowska-Daniel I; Pejsak Z; Szmigielski S; Sokolska G; Jeljaszewicz J; Pulverer G
    Zentralbl Bakteriol; 1992 Dec; 277(4):538-46. PubMed ID: 1303696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic application of Propionibacterium avidum KP-40 in swine with acute experimental infections. II. Bacterial infections: pleuropneumonia and swine erysipelas.
    Markowska-Daniel I; Pejsak Z; Szmigielski S; Jeljaszewicz J; Pulverer G
    Dtsch Tierarztl Wochenschr; 1993 May; 100(5):185-8. PubMed ID: 8319545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant properties of Propionibacterium avidum KP-40 in vaccination against endemic viral and bacterial infections. III. Swine immunized with live attenuated Erysipelothrix rhusiopathiae vaccine and experimentally infected with virulent strains R203 and R270B of E. rhusiopathiae.
    Markowska-Daniel I; Pejsak Z; Szmigielski S; Sokolska G; Jeljaszewicz J; Pulverer G
    Zentralbl Bakteriol; 1992 Dec; 277(4):547-53. PubMed ID: 1303697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant properties of propionibacterium avidum KP-40 in vaccination against endemic viral and bacterial infections. I. Swine immunized with live attenuated Aujeszky's disease virus vaccine and experimentally infected with virulent viruses.
    Markowska-Daniel I; Pejsak Z; Szmigielski S; Jeljaszewicz J; Pulverer G
    Zentralbl Bakteriol; 1992 Dec; 277(4):529-37. PubMed ID: 1338942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies.
    Ramjeet M; Deslandes V; Gouré J; Jacques M
    Anim Health Res Rev; 2008 Jun; 9(1):25-45. PubMed ID: 18346296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of the combined vaccine prepared from cell-free-antigen of Actinobacillus pleuropneumoniae serotypes 1, 2 and 5 in pigs.
    Oishi E; Kitajima T; Koyama Y; Ohgitani T; Katayama S; Okabe T
    J Vet Med Sci; 1995 Dec; 57(6):1125-8. PubMed ID: 8720063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs.
    van den Bosch H; Frey J
    Vaccine; 2003 Sep; 21(25-26):3601-7. PubMed ID: 12922088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
    Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
    Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state.
    Hensel A; Huter V; Katinger A; Raza P; Strnistschie C; Roesler U; Brand E; Lubitz W
    Vaccine; 2000 Jul; 18(26):2945-55. PubMed ID: 10825595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosol treatment of pigs with Actinobacillus pleuropneumoniae serotype 2: mucosal immunity and resistance against challenge.
    Loftager MK; Eriksen L; Nielsen R
    Adv Exp Med Biol; 1995; 371B():1611-4. PubMed ID: 7502867
    [No Abstract]   [Full Text] [Related]  

  • 12. Selection of serotype-specific vaccine candidate genes in Actinobacillus pleuropneumoniae and heterologous immunization with Propionibacterium acnes.
    Lei L; Sun C; Lu S; Feng X; Wang J; Han W
    Vaccine; 2008 Nov; 26(49):6274-80. PubMed ID: 18835316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of mice and swine against infection with Actinobacillus pleuropneumoniae by vaccination.
    Beaudet R; McSween G; Boulay G; Rousseau P; Bisaillon JG; Descoteaux JP; Ruppanner R
    Vet Microbiol; 1994 Mar; 39(1-2):71-81. PubMed ID: 8203129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71.
    Zhang F; Zhao Q; Quan K; Zhu Z; Yang Y; Wen X; Chang YF; Huang X; Wu R; Wen Y; Yan Q; Huang Y; Ma X; Han X; Cao S
    PLoS One; 2018; 13(6):e0198207. PubMed ID: 29856812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae.
    Li L; Sun C; Yang F; Yang S; Feng X; Gu J; Han W; Langford PR; Lei L
    Vaccine; 2013 Oct; 31(45):5269-75. PubMed ID: 24051157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines.
    Tumamao JQ; Bowles RE; van den Bosch H; Klaasen HL; Fenwick BW; Blackall PJ
    Aust Vet J; 2004 Dec; 82(12):773-80. PubMed ID: 15648941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of an Actinobacillus pleuropneumoniae bacterin against serotypes 1, 3, 5 and 9.
    Tarasiuk K; Pejsak Z; Hogg A; Carlson MP
    Can Vet J; 1994 Apr; 35(4):233-8. PubMed ID: 8076279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the protective efficacy of Actinobacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs.
    Rioux S; Girard C; Dubreuil JD; Jacques M
    Res Vet Sci; 1998; 65(2):165-7. PubMed ID: 9839897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs.
    Furesz SE; Mallard BA; Bossé JT; Rosendal S; Wilkie BN; MacInnes JI
    Infect Immun; 1997 Feb; 65(2):358-65. PubMed ID: 9009283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge.
    Lu YC; Li MC; Chen YM; Chu CY; Lin SF; Yang WJ
    Vaccine; 2011 Oct; 29(44):7740-6. PubMed ID: 21835218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.